Health Care·Pharmaceuticals·$3.4B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.26 | N/A | +6.14% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.26 | N/A | +6.14% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed satisfaction with the quarter's performance, particularly regarding their ongoing projects. They emphasized their commitment to pipeline development.
We are pleased with our progress this quarter.
Our focus remains on advancing our pipeline.
Edgewise Therapeutics reported a narrower-than-expected loss per share, which led to a positive stock reaction, with shares rising 4.61%. The company did not provide revenue figures or future guidance, leaving investors focused on the EPS beat and management's optimistic tone about their pipeline. This performance may bolster investor confidence as they await further developments.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TELADOC HEALTH INC
Feb 22, 2022